ALLERNAZE

LOE Approaching

triamcinolone acetonide

NDANASALSPRAY, METERED
Approved
Feb 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6

Mechanism of Action

CLINICAL PHARMACOLOGY: Triamcinolone acetonide is a more potent derivative of triamcinolone. Triamcinolone acetonide is approximately eight times more potent than prednisone in animal models of inflammation. The clinical significance of this is unclear. Although the precise mechanism of…

Indications (4)

the nasal symptoms of seasonalperennial allergic rhinitis in adultschildren 12 years of ageolder

Clinical Trials (5)

NCT04598542Phase 1Completed

Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers

Started Oct 2020
NCT02294656Phase 1Completed

Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

Started Nov 2014
4 enrolled
CYSTOID MACULAR EDEMA
NCT00449072Phase 4Completed

Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)

Started Mar 2007
299 enrolled
Rhinitis, Allergic, Perennial
NCT00476918Phase 1Unknown

Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema

Started Jul 2006
60 enrolled
Diabetic RetinopathyDiabetic Macular Edema
NCT00242580Phase 3Completed

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

Started Sep 2005
111 enrolled
Macular DegenerationChoroidal Neovascularization
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers